/JAZZ
JAZZ Stock - Jazz Pharmaceuticals plc
Healthcare|BiotechnologyNASDAQ
$166.99+0.60%
+$0.99 (+0.60%) • Dec 19
82
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.96
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).79
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+14.6%upside
Target: $191.37
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for JAZZ
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$165.32 – $168.66
TARGET (TP)$191.29
STOP LOSS$153.63
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.31
52W High$182.99
52W Low$95.49
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $4.07B | $3.83B | $3.66B | $3.09B | $2.36B |
| Gross Profit | $3.62B | $3.40B | $3.12B | $2.65B | $2.21B |
| Gross Margin | 89.0% | 88.6% | 85.2% | 85.8% | 93.7% |
| Operating Income | $716.63M | $578.58M | $-65,528,000 | $170.28M | $378.07M |
| Net Income | $560.12M | $414.83M | $-224,060,000 | $-328,954,000 | $238.62M |
| Net Margin | 13.8% | 10.8% | -6.1% | -10.6% | 10.1% |
| EPS | $9.06 | $6.55 | $-3.58 | $-5.51 | $4.28 |
Company Overview
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
55%
Hold / Neutral
5
45%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
6 Bullish5 Neutral/Bearish
Price Targets
$171
Average Target
↑ 2.2% Upside
Now
$135
Low
$171
Average
$196
High
Based on 12 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 24th 2025 | UBS | Downgrade | Neutral | $188 |
| July 15th 2025 | Deutsche Bank | Initiation | Buy | $152 |
| March 7th 2025 | UBS | Upgrade | Buy | $179← $145 |
| February 26th 2025 | Cantor Fitzgerald | Downgrade | Neutral | - |
| February 13th 2025 | Wells Fargo | Upgrade | Overweight | $170← $130 |
| December 12th 2024 | Morgan Stanley | Upgrade | Overweight | $175← $140 |
| June 5th 2024 | Goldman | Initiation | Buy | $169 |
| January 3rd 2024 | Robert W. Baird | Initiation | Outperform | $160 |
| November 27th 2023 | UBS | Downgrade | Neutral | $135← $170 |
| September 29th 2023 | Raymond James | Initiation | Market Perform | - |
| June 12th 2023 | Wells Fargo | Resumed | Equal Weight | $140← $184 |
| December 9th 2022 | Goldman | Upgrade | Buy | $190← $192 |
| June 14th 2022 | UBS | Initiation | Buy | $194 |
| April 6th 2022 | Goldman | Downgrade | Neutral | $196← $202 |
Earnings History & Surprises
JAZZBeat Rate
56%
Last 18 quarters
Avg Surprise
-6.2%
EPS vs Estimate
Beats / Misses
10/8
Last 12 quarters
Latest EPS
$8.13
Q4 2025
EPS Surprise History
Q1 24
-4.6%
$5.02vs$5.26
Q2 24
-35.3%
$2.68vs$4.14
Q3 24
+13.2%
$5.30vs$4.68
Q4 24
+20.8%
$6.61vs$5.47
Q1 25
+13.2%
$6.60vs$5.83
Q2 25
-62.7%
$1.68vs$4.51
Q3 25
-34.8%
$-8.25vs$-6.12
Q4 25
+36.6%
$8.13vs$5.95
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 24, 2026 | $6.41 | — | — | — |
Q4 2025 | Nov 5, 2025 | $5.95 | $8.13 | +36.6% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $-6.12 | $-8.25 | -34.8% | ✗ MISS |
Q2 2025 | May 6, 2025 | $4.51 | $1.68 | -62.7% | ✗ MISS |
Q1 2025 | Feb 25, 2025 | $5.83 | $6.60 | +13.2% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $5.47 | $6.61 | +20.8% | ✓ BEAT |
Q3 2024 | Jul 31, 2024 | $4.68 | $5.30 | +13.2% | ✓ BEAT |
Q2 2024 | May 1, 2024 | $4.14 | $2.68 | -35.3% | ✗ MISS |
Q1 2024 | Feb 28, 2024 | $5.26 | $5.02 | -4.6% | ✗ MISS |
Q4 2023 | Nov 8, 2023 | $4.90 | $4.84 | -1.2% | ✗ MISS |
Q3 2023 | Aug 9, 2023 | $4.46 | $4.51 | +1.1% | ✓ BEAT |
Q2 2023 | May 10, 2023 | $4.26 | $3.95 | -7.3% | ✗ MISS |
Q1 2023 | Mar 1, 2023 | $0.51 | $-0.07 | -113.7% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $4.72 | $5.17 | +9.5% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $4.20 | $4.30 | +2.4% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $3.75 | $3.73 | -0.5% | ✗ MISS |
Q1 2022 | Mar 1, 2022 | $3.71 | $4.21 | +13.5% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $3.27 | $4.20 | +28.4% | ✓ BEAT |
Q3 2021 | Aug 3, 2021 | $3.55 | $3.90 | +9.9% | ✓ BEAT |
Latest News
Piper Sandler Reiterates Overweight on Jazz Pharmaceuticals, Raises Price Target to $219
📈 PositiveBenzinga•Dec 10, 2025, 04:47 PM
Jazz Pharma To Present Eight Abstracts, Including Four Late-Breaking, On Epidiolex, At AES 2025 Annual Meeting
📈 PositiveBenzinga•Dec 5, 2025, 02:07 PM
Jazz Pharmaceuticals To Present Phase 3 Results Of Ziihera Combinations In First-Line HER2-Positive Locally Advanced Or Metastatic Gastroesophageal Adenocarcinoma
📈 PositiveBenzinga•Dec 2, 2025, 09:12 PM
UBS Downgrades Jazz Pharmaceuticals to Neutral, Raises Price Target to $188
➖ NeutralBenzinga•Nov 24, 2025, 01:29 PM•Also:
Wells Fargo Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $235
📈 PositiveBenzinga•Nov 18, 2025, 07:21 PM
Jazz Pharmaceuticals shares are trading higher after multiple analysts raised their respective prices targets on the stock following the company's recent phase 3 Ziihera combination therapy data.
📈 PositiveBenzinga•Nov 18, 2025, 04:40 PM
Baird Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $209
📈 PositiveBenzinga•Nov 18, 2025, 03:26 PM
B of A Securities Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $247
📈 PositiveBenzinga•Nov 18, 2025, 12:31 PM
Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $205
📈 PositiveBenzinga•Nov 17, 2025, 05:37 PM
Jazz Pharmaceuticals shares are trading higher after the company announced top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra, as first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma, including cancers of the stomach, gastroesophageal junction and esophagus.
📈 PositiveBenzinga•Nov 17, 2025, 01:37 PM
Jazz Pharmaceuticals Released Topline Results From Phase 3 HERIZON-GEA-01 Trial Of Ziihera (Zanidatamab-hrii) In Combination With Chemotherapy, With Or Without Tevimbra (Tislelizumab) For Untreated HER2+ Locally Advanced Or Metastatic Gastroesophageal Adenocarcinoma
➖ NeutralBenzinga•Nov 17, 2025, 11:11 AM
Jazz Pharma To Highlight Both Clinical And Preclinical Research Evaluating Modeyso And New Preclinical Data Featuring JZP3507 In CNS Tumors, At 2025 SNO Annual Meeting
➖ NeutralBenzinga•Nov 11, 2025, 12:48 PM
RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $155
📈 PositiveBenzinga•Nov 6, 2025, 04:15 PM
Jazz Pharmaceuticals Raises FY2025 GAAP EPS Guidance from $(9.25)-$(7.50) to $(7.10)-$(5.20) vs $(7.76) Est
📈 PositiveBenzinga•Nov 5, 2025, 09:18 PM
Jazz Pharmaceuticals Raises FY2025 Adj EPS Guidance from $4.80-$5.60 to $7.65-$8.45 vs $5.33 Est; Narrows FY2025 Sales Guidance from $4.150B-$4.300B to $4.175B-$4.275B vs $4.221B Est
📈 PositiveBenzinga•Nov 5, 2025, 09:18 PM
Jazz Pharmaceuticals Q3 Adj. EPS $8.13 Beats $5.92 Estimate, Sales $1.126B Beat $1.109B Estimate
📈 PositiveBenzinga•Nov 5, 2025, 09:15 PM
JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Lowers Price Target to $199
➖ NeutralBenzinga•Oct 27, 2025, 02:32 PM
Avadel settles with Jazz Pharma; agrees to be acquired by Alkermes
📈 PositiveSeeking Alpha•Oct 22, 2025, 11:20 AM•Also: ,
Avadel Pharma Announces Global Settlement Of All Litigation With Jazz Pharma
📈 PositiveBenzinga•Oct 22, 2025, 10:34 AM•Also:
Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $180
📈 PositiveBenzinga•Oct 20, 2025, 03:36 PM
Frequently Asked Questions about JAZZ
What is JAZZ's current stock price?
Jazz Pharmaceuticals plc (JAZZ) is currently trading at $166.99 per share. The stock has moved +0.60% today.
What is the analyst price target for JAZZ?
The average analyst price target for JAZZ is $191.29, based on 1 analyst.
What sector is Jazz Pharmaceuticals plc in?
Jazz Pharmaceuticals plc operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is JAZZ's market cap?
Jazz Pharmaceuticals plc has a market capitalization of $10.15 billion, making it a large-cap company.
Does JAZZ pay dividends?
No, Jazz Pharmaceuticals plc does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABVX
Abivax S.A.
$114.94
Mkt Cap: $7.5B
AXSM
Axsome Therapeutics, Inc.
$152.65
Mkt Cap: $7.7B
CAI
Caris Life Sciences, Inc.
$27.94
Mkt Cap: $7.9B
CYTK
Cytokinetics, Incorporated
$62.72
Mkt Cap: $7.5B
HALO
Halozyme Therapeutics, Inc.
$67.35
Mkt Cap: $7.9B
MDGL
Madrigal Pharmaceuticals, Inc.
$591.02
Mkt Cap: $13.1B
MRUS
Merus N.V.
$97.01
Mkt Cap: $7.4B
NUVL
Nuvalent, Inc.
$103.80
Mkt Cap: $7.5B
RNA
Avidity Biosciences, Inc.
$72.34
Mkt Cap: $9.5B
RYTM
Rhythm Pharmaceuticals, Inc.
$112.14
Mkt Cap: $7.5B
Explore stocks similar to JAZZ for comparison